Tirzepatide
Review a related dual GIP/GLP-1 guide for comparison points and clinician discussion questions.
What it is
Semaglutide is a GLP-1 receptor agonist used in FDA-approved products for chronic weight management and diabetes indications. New Blue discusses clinician-supervised compounded semaglutide pathways, but compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality.
Why patients explore Semaglutide
- Appetite regulation - often reviewed alongside nutrition and follow-up planning
- Weekly dosing and titration - usually structured with gradual escalation
- Side-effect review - GI tolerability and hydration matter
- Refill continuity - treatment interruptions can change next-step planning
How it compares to related options
What your clinician may review
- Review prior GLP-1 use, history of pancreatitis or gallbladder symptoms, personal or family history of medullary thyroid carcinoma or MEN 2, pregnancy plans, current medications, and your ability to follow a weekly titration schedule. Your clinician should also discuss follow-up timing and what symptoms should trigger a hold, call, or escalation.
Frequently Asked Questions
How quickly will I see results?
Response varies by person, dose-titration pace, and the overall care plan.
What makes this different from branded semaglutide products?
Compounded semaglutide discussed through New Blue is prepared by state-licensed 503A compounding pharmacies when prescribed. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality.
Who may want to discuss semaglutide with a clinician?
Adults 21+ who are physically located in a covered state and are seeking clinician-supervised weight management may want to discuss semaglutide. Fit depends on medical history, current medications, contraindications, side-effect tolerance, and treatment goals.
What should I review with my clinician before starting semaglutide?
Review prior GLP-1 use, history of pancreatitis or gallbladder symptoms, personal or family history of medullary thyroid carcinoma or MEN 2, pregnancy plans, current medications, and your ability to follow a weekly titration schedule. Your clinician should also discuss follow-up timing and what symptoms should trigger a hold, call, or escalation.
When should I contact my clinician or seek urgent care?
Severe or worsening symptoms, signs of allergic reaction, chest pain, trouble breathing, neurologic symptoms, or inability to keep fluids down should prompt urgent evaluation. Telehealth is not emergency care. Call 911 or go to the nearest emergency department for life-threatening symptoms.
Are results guaranteed?
No. Eligibility, tolerability, and outcomes vary by person. Prescriptions are never automatic or guaranteed, and treatment decisions are made by a licensed clinician based on your history, current medications, contraindications, and goals.
Medical review & editorial standards
This page is educational content from the New Blue Health Clinical Content Team. It is reviewed under the New Blue Health Medical Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.